Enrollment in Phase II Clinical Trial for ACCRUFeR

AI SummaryClose X

Shield Therapeutics plc announced that its partner, MEDLEAP Pharma, has enrolled the first patient in a Phase II clinical trial for ACCRUFeR® (ferric maltol) in Japan for the treatment of Pulmonary Arterial Hypertension (PAH). This exploratory study is designed to support a future Phase III trial, following the Japanese Pharmaceuticals and Medical Devices Agency's confirmation of the development plan based on prior European, UK, and US trial results. The PAH market in Japan is estimated at over $230 million in 2024, with iron supplementation strongly recommended for PAH patients with iron deficiency anemia.

Disclaimer*

UK 100

Latest directors dealings